We thought it would never work. Until now.
For decades, pancreatic cancer has occupied a grim corner of medicine where diagnosis and death arrived almost together. Now, at a major oncology conference in Chicago, researchers have presented evidence that a drug called daraxonrasibe — by targeting the genetic root of ninety percent of these tumors — has doubled survival time and returned something precious to patients: months of life lived without consuming pain. The result is not yet a cure, but it is the clearest signal in a generation that this disease may finally be yielding to human understanding.
- Pancreatic cancer has long resisted treatment because its dominant mutation, in the KRAS gene, defeated every molecular strategy scientists borrowed from other cancers — until now.
- In a 500-patient trial across six countries, daraxonrasibe kept 55% of patients alive at one year, compared to just 18% on standard chemotherapy, a gap so stark that doctors at the conference rose to applaud.
- Beyond survival, the drug offered relief from the severe, nerve-crushing pain that defines this disease, and held tumors at bay for more than seven months before progression — twice as long as chemotherapy managed.
- Researchers are now eyeing the drug as a pre-surgical tool to shrink tumors away from vital blood vessels, potentially making inoperable cases operable and opening a path toward actual cure.
- Further still, early animal studies suggest daraxonrasibe may one day be used preventively — administered to people whose blood tests reveal dangerous mutations before cancer even takes hold.
At a major oncology conference in Chicago, researchers unveiled results that could redefine one of medicine's most stubborn problems. A drug called daraxonrasibe, tested in a trial called RASolute-302 across five hundred patients in six countries, kept fifty-five percent of participants alive after one year. Among those who received standard chemotherapy, only eighteen percent reached that mark. On average, the drug doubled survival time — an extraordinary outcome in a disease that has resisted meaningful progress for decades.
What moved doctors beyond the numbers was the quality of life the drug returned. Patients on daraxonrasibe remained cancer-free for roughly seven and a half months before the disease returned, compared to less than three and a half months for those on chemotherapy. The drug also reduced the severe pain pancreatic tumors inflict by limiting how aggressively they invade nerves and blood vessels — something chemotherapy rarely achieves.
The biological breakthrough behind daraxonrasibe is as significant as its clinical results. More than ninety percent of pancreatic tumors carry mutations in the KRAS gene, a target scientists had pursued for years without success. The protein KRAS activates in pancreatic cancer grips its molecular trigger so tightly that conventional blocking strategies — effective in breast and lung cancers — simply couldn't compete. Revolution Medicines took a different approach: rather than jamming the lock, daraxonrasibe acts as a doorstop, preventing the protein from ever switching on. It works across KRAS mutations and, remarkably, in the smaller share of patients with other RAS mutations as well.
Oncologist Pedro Uson of Einstein Hospital in São Paulo sees the drug's future extending beyond treatment. Administered before surgery, it could shrink tumors currently pressed against vital blood vessels — making the inoperable operable. Combined with post-surgical use to eliminate escaped cancer cells, this sequence could transform pancreatic cancer into something survivable, even curable. Further out, Uson imagines liquid biopsy blood tests detecting dangerous mutations before cancer develops, allowing preventive treatment with daraxonrasibe. Early animal studies, in which pre-cancerous lesions disappeared after treatment, suggest this vision is not entirely remote. The distance between science fiction and clinical reality, in this disease at least, appears to be closing.
At a major oncology conference in Chicago, researchers presented results that may reshape how doctors treat one of cancer's cruelest forms. A drug called daraxonrasibe, tested on five hundred patients across six countries, kept fifty-five percent of them alive after one year. Those given standard chemotherapy? Eighteen percent survived that long. The difference amounts to an extra thirteen months of life on average—a doubling of survival time in a disease that has resisted effective treatment for decades.
The trial, called RASolute-302, enrolled men and women with pancreatic cancer that had already spread. Half received the new drug as a daily pill. Half received chemotherapy. What made doctors stand and applaud wasn't just the survival numbers, though those alone represent a watershed moment. The drug also gave patients something chemotherapy rarely offers: relief from the severe pain that pancreatic tumors inflict. Patients on daraxonrasibe remained cancer-free for an average of seven and a half months before the disease returned. Those on chemotherapy saw their cancer come back in less than three and a half months.
Pedro Uson, an oncologist at Einstein Hospital in São Paulo who attended the conference, sees something larger emerging. "We can now say patients will have better chances of keeping the disease controlled," he explained. But his real excitement centers on what comes next. Once approved, daraxonrasibe could be given before surgery to shrink tumors that are currently considered inoperable—those nestled against vital blood vessels like the mesenteric artery, which feeds the intestines. Removing such tumors risks catastrophic bleeding. If the drug can pull them away from these vessels, surgeons could operate. Combined with the medication afterward to catch any escaped cancer cells, this approach could transform pancreatic cancer from a death sentence into something survivable, even curable.
Why did it take until 2026 for such a drug to emerge? The answer lies in the biology of pancreatic cancer itself. More than ninety percent of pancreatic tumors carry mutations in a gene called KRAS, which belongs to a family of cancer-driving genes. For years, scientists tried to block KRAS the same way they'd successfully blocked similar mutations in breast and lung cancers—by creating fake molecular keys that would jam the lock and prevent the real key from activating the cancer. The approach worked elsewhere. It never worked for pancreas cancer. The protein that KRAS activates in pancreatic tumors, called GTPase, grips the real key with such ferocity that no fake key could compete. "We thought it would never work," Uson recalled.
Then Revolution Medicines developed daraxonrasibe, which operates on an entirely different principle. Rather than trying to block the lock, the drug acts like a doorstop, preventing the activation of the protein that triggers malignant cell multiplication. Remarkably, it works not only on KRAS-driven tumors but also on the five percent of patients in the trial who carried other RAS mutations. This broad effectiveness means daraxonrasibe could become the first-line treatment—the drug doctors reach for immediately upon diagnosis—potentially yielding even better results than the trial showed.
The side effects proved manageable: skin rashes and gastrointestinal symptoms that doctors could control. Beyond survival, the drug offers another possibility. By reducing how aggressively tumors invade blood vessels and nerves, it diminishes the excruciating pain pancreatic cancer causes. It also starves tumors by blocking the formation of new blood vessels that would feed them. Some evidence suggests the cancer could stabilize on a plateau, transforming from a rapidly fatal disease into a chronic condition managed with a daily pill.
Yet prevention remains the stronger path. Excessive alcohol, smoking, obesity, and diets heavy in red meat and processed foods all increase pancreatic cancer risk—factors the Pan-American Health Organization and International Agency for Research on Cancer have identified as modifiable. Only fifteen percent of pancreatic cancers are hereditary; the rest likely stem from lifelong exposure to toxins, from industrial foods in childhood to microplastics to adolescent smoking. In a separate study published recently in Science, researchers gave daraxonrasibe to mice with pre-cancerous pancreatic lesions and watched them disappear. The leap from mice to humans remains vast. But Uson imagines a future where a simple blood test—a liquid biopsy—detects KRAS mutations before cancer develops, allowing doctors to treat patients preventively with daraxonrasibe. It sounds like science fiction. It may not be.
Notable Quotes
We can now say patients will have better chances of keeping the disease controlled, and in the future, this molecule could be given before surgery to make inoperable tumors resectable.— Pedro Uson, oncologist at Einstein Hospital, São Paulo
Daraxonrasibe appears to be a pan-RAS molecule that acts on all mutations in this gene, so it should be the preferred choice for treatment.— Pedro Uson, oncologist
The Hearth Conversation Another angle on the story
Why did pancreatic cancer resist treatment for so long when other cancers have improved so dramatically?
Because the mechanism that drives it is fundamentally different. The protein that KRAS activates in pancreatic tumors grips its molecular key so tightly that the fake keys scientists created elsewhere simply couldn't compete. It's like trying to jam a lock that's already been designed to resist jamming.
So daraxonrasibe works by a completely different mechanism?
Exactly. Instead of trying to block the lock, it prevents the door from opening in the first place. It's a doorstop, not a key. That's why it succeeded where everything else failed.
The survival numbers are striking, but you mentioned the real excitement is about what comes next. What do you mean?
Right now, the drug is being used after chemotherapy has already failed—it's a second-line treatment. But if it works this well as a second line, imagine using it first, or even before surgery to shrink tumors that are currently too dangerous to remove. That's where the cure becomes possible.
You mentioned tumors stuck to blood vessels. Why is that such a problem?
Because removing them risks destroying the vessel and causing fatal bleeding. If daraxonrasibe can pull the tumor away from the vessel, suddenly surgery becomes safe. And if you can remove the tumor surgically and then use the drug to catch any cells that escaped, you've fundamentally changed the outcome.
Is this a cure or a chronic disease management tool?
Possibly both. In the trial, the cancer seemed to stabilize on a plateau rather than continue spreading. That suggests it could become something you manage long-term with a daily pill, like diabetes. But if you catch it early enough and combine it with surgery, actual cure becomes realistic.
What about prevention? Can this drug prevent cancer from developing?
That's the dream. Mice with pre-cancerous lesions saw them disappear when given the drug. If doctors could detect KRAS mutations through a simple blood test before cancer develops, they might be able to treat people preventively. But that's still years away.